French pharma firm Sanofi to acquire US-based Blueprint Medicines for $9.1B

By Bahattin Gonultas and Mucahithan Avcioglu

BERLIN / ISTANBUL (AA) - France-based pharmaceutical company Sanofi stated Monday that it will acquire US-based Blueprint Medicines Corporation for $9.1 billion to expand its portfolio in rare immunological diseases.

Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, has accepted Sanofi's acquisition offer of $129 per share in cash, according to a statement from Sanofi.

The offer is around 27% above the $101.35 closing price of Blueprint shares last Friday.

"The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline," the statement said.

"Furthermore, Blueprint’s established presence among allergists, dermatologists, and immunologists is expected to enhance Sanofi’s growing immunology pipeline," it added.

The acquisition is expected to be completed in the third quarter of 2025 after the necessary permits.

Blueprint shareholders will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively.

Blueprint has the only drug approved for the treatment of SM, a rare disease caused by an excessive increase of mast cells in the body. The US company is also working on next-generation drugs for SM and drugs for various immune disorders.

The deal is the largest health care acquisition deal in Europe this year.

On the other hand, Sanofi acquired Vigil Neuroscience for $470 million last month. In January, the French company also acquired Vigil Neuroscience.